STOCK TITAN

INTEGRATED BIOPHARMA INC - $INBP STOCK NEWS

Welcome to our dedicated page for INTEGRATED BIOPHARMA news (Ticker: $INBP), a resource for investors and traders seeking the latest updates and insights on INTEGRATED BIOPHARMA stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect INTEGRATED BIOPHARMA's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of INTEGRATED BIOPHARMA's position in the market.

Rhea-AI Summary
Integrated BioPharma, Inc. reports a decrease in revenue for the quarter and six-month period ended December 31, 2023 compared to the same periods in 2022. Operating losses have increased for the quarter but decreased for the six-month period. The Company also experienced a higher net loss per share in 2023. The Co-CEOs aim to reduce reliance on major customers by expanding the customer base.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.04%
Tags
none
-
Rhea-AI Summary
Integrated BioPharma, Inc. (OTCQX:INBP) reports a 4.9% increase in revenue for the quarter ended September 30, 2023, with operating loss of $54,000. Net loss for the same period was $59,000 or $0.00 per share of common stock. The company's two largest customers in the Contract Manufacturing Segment represented approximately 91% and 85% of total revenue in the quarters ended September 30, 2023 and 2022, respectively.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Integrated BioPharma reports financial results for Q2 and FY 2023. Revenue for Q2 2023 decreased by 2.3% compared to Q2 2022. Operating income for Q2 2023 was $79,000, a decrease from $438,000 in Q2 2022. Revenues for FY 2023 decreased by 9.8% compared to FY 2022. Operating income for FY 2023 was $120,000, a decrease from $2.7 million in FY 2022. Net income for Q2 2023 was $40,000, a decrease from $1.5 million in Q2 2022. Net loss for FY 2023 was $34,000, a decrease from net income of $3.8 million in FY 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.88%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.07%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.78%
Tags
none
INTEGRATED BIOPHARMA INC

OTC:INBP

INBP Rankings

INBP Stock Data

6.47M
9.40M
79.76%
0.07%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
Hillside

About INBP

integrated biopharma inc is a pharmaceuticals company based out of 225 long avenue, hillside, new jersey, united states.